Boston Pharma’s once-monthly injection efimosfermin alfa offers a convenient dosing option for MASH patients while also ...
Analysts appear optimistic for Intellia’s gene editor nex-z, which showed a greater serum TTR reduction than Alnylam’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback